Why the study?
Does the PDGF receptor inhibitor STI571 reverse pulmonary vascular changes in animal models of pulmonary hypertension?
Does the PDGF receptor inhibitor STI571 reverse pulmonary vascular changes in animal models of pulmonary hypertension?
The PDGF receptor inhibitor STI571 reverses pulmonary vascular changes in animal models, providing preclinical proof of concept for its development as a targeted therapy for pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Supports PDGF inhibition for established pulmonary vascular disease; leaves open translation to human pulmonary hypertension pending clinical trials.
R. J. Barst (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: